Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
Fábio Rocha Formiga, Roger LeBlanc, Juliana de Souza Rebouças, et al.
Journal of Controlled Release (2020) Vol. 329, pp. 758-761
Open Access | Times Cited: 78

Showing 26-50 of 78 citing articles:

Extracellular binding sites of positive and negative allosteric P2X4 receptor modulators
Stephanie Weinhausen, Jessica Nagel, Vigneshwaran Namasivayam, et al.
Life Sciences (2022) Vol. 311, pp. 121143-121143
Closed Access | Times Cited: 14
Ameliorating the antiparasitic activity of the multifaceted drug ivermectin through a polymer nanocapsule formulation
Zilyane Cardoso de Souza, Francisco Humberto Xavier Júnior, Irapuan Oliveira Pinheiro, et al.
International Journal of Pharmaceutics (2023) Vol. 639, pp. 122965-122965
Closed Access | Times Cited: 8
Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study
Suzan M. Mansour, Rehab Nabil Shamma, Kawkab A. Ahmed, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108004-108004
Open Access | Times Cited: 17
Is Ivermectin Effective in Treating COVID-19?
Shuangshuang Yang, Shan Shen, Ning Hou
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 11
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial
Anan Manomaipiboon, Kittisak Pholtawornkulchai, Sujaree Poopipatpab, et al.
Trials (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Synthesis and Antiviral Efficacy of Pyrimidine Analogs Targeting Viral Pathways
N. Jeelan Basha, T. L. Chandana
ChemistrySelect (2023) Vol. 8, Iss. 19
Closed Access | Times Cited: 6
COVID-19 and Ivermectin: Potential threats associated with human use
Tean Zaheer, Kaushik Pal, Rao Zahid Abbas, et al.
Journal of Molecular Structure (2021) Vol. 1243, pp. 130808-130808
Open Access | Times Cited: 12
The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells
Theodoros Kelesidis, Madhav Sharma, Anton Petcherski, et al.
Virulence (2021) Vol. 12, Iss. 1, pp. 2214-2227
Open Access | Times Cited: 12
Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials
Qinglin Cheng, Gang Zhao, Chen Jun-fang, et al.
Medicine (2022) Vol. 101, Iss. 41, pp. e30998-e30998
Open Access | Times Cited: 9
Identification of the shared gene signatures between pulmonary fibrosis and pulmonary hypertension using bioinformatics analysis
Hui Zhao, Lan Wang, Yi Yan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Comparative Evaluation of Different Antivirals against Lumpy Skin Disease in Cattle
Rather Izhar Ul Haq, Amatul Muhee, Oveas Raffiq Parray, et al.
Journal of Pure and Applied Microbiology (2024) Vol. 18, Iss. 3, pp. 1807-1823
Open Access | Times Cited: 1
COVID-19 and strongyloidiasis: what to expect from this coinfection?
Carolina Victoria Marcitelli Pereira, Giovanna Ribeiro Achur Mastandrea, Ana Clara Cassine de Souza Medeiros, et al.
Clinics (2021) Vol. 76, pp. e3528-e3528
Open Access | Times Cited: 10
Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis
Saeid Mezail Mawazi, Nousheen Fathima, Syed Uzair Mahmood, et al.
The American Journal of Emergency Medicine (2024) Vol. 85, pp. 98-107
Closed Access | Times Cited: 1
Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway
Huiyang Liu, Zhirong Chai, Ya Gao, et al.
Acta Biochimica et Biophysica Sinica (2024)
Open Access | Times Cited: 1
SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases
Gonzalo Ferreira, Axel Santander, Florencia Savio, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2021) Vol. 1867, Iss. 12, pp. 166264-166264
Open Access | Times Cited: 8
The use of Ivermectin for the treatment of COVID-19: Panacea or enigma?
Helen Onyeaka, Phemelo Tamasiga, Joy Onyinyechi Chionuma, et al.
Clinical Epidemiology and Global Health (2022) Vol. 16, pp. 101074-101074
Open Access | Times Cited: 6
Evaluation of Antiviral Activity of Ivermectin against Infectious Bovine Rhinotracheitis Virus in Rabbit Model
Chen Wang, Yingyu Chen, Xi Chen, et al.
Animals (2023) Vol. 13, Iss. 20, pp. 3164-3164
Open Access | Times Cited: 3
Efficacy and Safety of Novel Oral Antivirals in Hospitalized COVID-19 Patients: A Network Meta-Analysis of Randomized Clinical Trials
Haoshuang Liu, Jingfeng Chen, Weihao Shao, et al.
Clinical Epidemiology (2023) Vol. Volume 15, pp. 1041-1053
Open Access | Times Cited: 3
Modulation of P2X 4 receptor activity by ivermectin and 5‐BDBD has no effect on the development of ARPKD in PCK rats
Biyang Xu, Oksana Nikolaienko, Vladislav Levchenko, et al.
Physiological Reports (2022) Vol. 10, Iss. 21
Open Access | Times Cited: 5
Evaluation of ivermectin antiviral activity against avian infectious bronchitis virus using a chicken embryo model
Donald L. Reynolds, E. Barry Simpson
International Journal of Veterinary Science and Medicine (2022) Vol. 10, Iss. 1, pp. 19-24
Open Access | Times Cited: 5
COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies
Vishal Singh, Himani Chaurasia, Richa Mishra, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 27, pp. 2211-2233
Closed Access | Times Cited: 4
Ivermectin Attenuates CCl4-Induced Liver Fibrosis in Mice by Suppressing Hepatic Stellate Cell Activation
Hanglu Ying, Long Li, Yufen Zhao, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 16043-16043
Open Access | Times Cited: 4
Seguridad y eficacia de ivermectina en tiempos de COVID-19
Arturo Pareja Cruz, Julio César Luque Espino
Horizonte Médico (Lima) (2020) Vol. 21, Iss. 1, pp. e1331-e1331
Open Access | Times Cited: 5
Ivermectin Affects Neutrophil-Induced Inflammation through Inhibition of Hydroxylysine but Stimulation of Cathepsin G and Phenylalanine Secretion
Svetlana I. Galkina, Ekaterina A. Golenkina, Marina V. Serebryakova, et al.
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3284-3284
Open Access | Times Cited: 3
Formulation and Ex Vivo Evaluation of Ivermectin Within Different Nano-Drug Delivery Vehicles for Transdermal Drug Delivery
Eunice Maureen Steenekamp, Wilna Liebenberg, Hendrik J. R. Lemmer, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1466-1466
Open Access

Scroll to top